NCT02186509 2025-04-30
Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas
Thomas Jefferson University
Phase 1 Completed
Clinical Trials
19 trialsNCT04479306 2024-06-04
Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01924260 2022-08-02
Alisertib and Gemcitabine Hydrochloride in Treating Patients With Solid Tumors or Pancreatic Cancer
University of California, Davis
Phase 1 Completed
NCT02327169 2020-02-25
A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies
Takeda
Phase 1 Completed
NCT02259010 2019-09-20
A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Alisertib in Participants With Advanced Solid Tumors or Relapsed/Refractory Lymphoma
Takeda
Phase 1 Completed
NCT01639911 2019-07-22
Phase I Study of MLN8237 and Pazopanib in Patients With Solid Tumors
University of Illinois at Chicago
Phase 1 Completed
NCT01898078 2019-06-21
Food Effect Study of Alisertib (MLN8237) in Participants With Advanced Solid Tumors or Lymphomas
Takeda
Phase 1 Completed
NCT01844583 2019-03-25
Safety, Tolerability and Pharmacokinetic (PK) of Concomitant Esomeprazole and Rifampin, and QT Study on Single and Multiple-doses of Alisertib
Takeda
Phase 1 Completed
NCT00651664 2019-03-15
A Phase I Clinical and Pharmacodynamic Study of MLN8237, A Novel Aurora A Kinase Inhibitor, in Participants With Advanced Malignancies
Takeda
Phase 1 Completed
NCT00500903 2019-03-14
A Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Participants With Advanced Solid Tumors
Takeda
Phase 1 Completed
NCT00962091 2019-03-12
Study of MLN8237 in Participants With Advanced Solid Tumors
Takeda
Phase 1 Completed
NCT01094288 2019-02-15
A Phase 1 Study of Alisertib Participants With Advanced Solid Tumors Including Castration-Resistant Prostate Cancer Receiving a Standard Docetaxel Regimen
Takeda
Phase 1 Completed
NCT01897012 2019-01-28
Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas
National Cancer Institute (NCI)
Phase 1 Completed
NCT01923337 2019-01-04
Irinotecan and Alisertib in Treating Patients With Advanced Solid Tumors or Colorectal Cancer
University of California, Davis
Phase 1 Completed
NCT01714947 2018-10-31
Mass Balance, Pharmacokinetics and Metabolism Study of Alisertib
Takeda
Phase 1 Completed
NCT02319018 2018-10-09
Alisertib and Combination Chemotherapy in Treating Patients With Gastrointestinal Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT01540682 2018-08-29
MLN8237 in Head and Neck Cancer
Abramson Cancer Center at Penn Medicine
Phase 1 Completed
NCT01677559 2018-01-11
Combining MLN8237 With Nab-Paclitaxel in Patients With Advanced Solid Malignancies
Washington University School of Medicine
Phase 1 Completed
NCT02444884 2016-02-09
MLN8237 to Treat Children With Relapsed/Refractory Solid Tumors
Children's Oncology Group
Phase 1 Completed